Latest news


Invitation to third quarter 2018 presentation

Posted on Nov 6, 2018

Oslo, Norway, 06 November 2018 – PCI Biotech invites to a presentation of the company’s third quarter 2018 report on Tuesday 13 November 2018 at Oslo Cancer Cluster Innovation Park. Time: Tuesday November 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, […]

Capital increase registered and listing of new shares

Posted on Oct 24, 2018

Oslo, Norway, 24 October 2018. Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the issuance of 170,000 new shares following exercise of employee share options in the Company. The  share capital increase resolved by the Board of Directors following the share option exercise […]

PCI Biotech to present Phase I dose escalation results at ESMO

Posted on Oct 19, 2018

Oslo, Norway, 19 October 2018 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company will present results from the Phase I dose escalation study in perihilar cholangiocarcinoma (extrahepatic bile duct cancer) at the ESMO 2018 Congress in Munich, Germany (19 – 23 October 2018). One of the key investigators […]